Reports
U.S. Large Molecule Drug Substance CDMO Market Business Trends, Strategies, and Forecasts, 2026-2034
REPORT DETAILS
REPORT DETAILS
ABOUT THIS REPORT
U.S. Large Molecule Drug Substance CDMO Market Overview
The U.S. large molecule drug substance CDMO market size was valued at USD 13.23 billion in 2025. The market is projected to grow at a CAGR of 7.5% from 2026 to 2034. Strategic investments in U.S. biomanufacturing capacity and rising healthcare expenditure are boosting the market growth.
Market Statistics
Key Takeaways
- The biologics segment led with a 77.25% revenue share in 2025. The segment's dominance is driven by the increased demand for monoclonal antibodies and cell and gene therapies.
- Biosimilars are projected to grow at a 7.5% CAGR. Patent expirations of several biologics are contributing to the segment's growth.
- Contract manufacturing held the largest market share of 67.05% in 2025. This is due to increasing dependence by pharmaceutical and biotechnology firms on CDMOs for high-volume GMP-capable production.
- Microbial systems are expected to register robust growth at a 8.2% CAGR. This is due to their efficiency and cost-effectiveness in the production of enzymes and peptides.
- Biotech firms led with a 54.30% revenue share in 2025. The segment's leading position is driven by its reliance on CDMOs for process development and commercial manufacturing.
Note: Figures and projections outlined in this report are the result of Polaris Market Research’s proprietary analytical processes, grounded in the latest available datasets and market observations.
Industry Dynamics
- Strategic investments by CDMOs and pharma giants are fueling large-scale biomanufacturing capacity growth throughout the U.S.
- Increasing healthcare spending and insurance coverage for biologic and specialty medicines is driving demand for outsourced large molecule drug substance development.
- High-cost production and rigorous regulatory validation requirements are still significant restraints, particularly for small and mid-sized CDMOs.
- AI-based digital twins, continuous bioprocessing, and modular buildings offer compelling opportunities for scalable and cost-effective manufacturing.
AI Impact on U.S. Large Molecule Drug Substance CDMO Market
- AI aids in enhancing large molecule drugs development through the analysis of biological information and fast-tracking the research process.
- It enhances production efficiency through optimization and minimization of errors in the production process.
- AI ensures quality control through real-time process monitoring and early detection of potential problems.
- It assists CDMOs in managing operations efficiently through predictive maintenance and workflow automation.
What is large molecule drug substance CDMO market comprises of?
The U.S. large molecule drug substance CDMO market comprises contract development and biologics manufacturing services including monoclonal antibodies, cell and gene therapies, recombinant proteins, and vaccines. These biopharma and biotech drug manufacturers support the pharma and biotech industry through process development, scale-up, cGMP manufacturing, and regulatory compliance. Increasing biopharmaceutical pipelines, biologics production technology innovation, and outsourcing are driving demand for customized CDMO expertise in the American market.
The increasingly growing pipeline of small and mid-size biotech monoclonal antibodies, cell therapies, and recombinant proteins is fueling greater reliance on CDMOs. They lack the required capital, specialized facilities, and regulatory expertise to manufacture large molecules internally.
Expansion of FDA fast-track, breakthrough therapy, and RMAT designations for next-generation biologics is further compressing approval timelines, forcing biopharma innovators to collaborate with CDMOs for timely process optimization, quick scale-up, and hassle-free tech transfer implementation within narrow regulatory windows.
Large Molecule vs Small Molecule Drug Manufacturing
| Factor | Large Molecule Manufacturing | Small Molecule Manufacturing |
| Size of Molecule | Complex and large biological molecules | Small chemically produced molecules |
| Method of Production | Cell-based bioprocessing | Chemical synthesis |
| Complexity of Production | Complex and sensitive | Relatively simpler production |
| Facility Requirements | Advanced bioreactors and aseptic facilities | Standard chemical plant equipment |
| Regulations | Biological standards for manufacture | Conventional pharmaceutical regulations |
Drivers & Opportunities
Which are the driving factors for U.S. large molecule drug substance CDMO market growth?
Strategic Investments Fueling U.S. Biomanufacturing Capacity Growth: Leading pharmaceutical, nutrition, and cosmetic companies are increasingly investing in CDMO partnerships to access advanced fermentation and biologics production infrastructure. In October 2025, Symrise AG executed a strategic equity investment in American biotech firm Cellibre, driving the growth of fermentation-derived flavor ingredients and cosmetic bioactives in the domestic market.
Rising Healthcare Expenditure Elevating Demand for Biologic Therapies
Increasing healthcare expenditure in the U.S. is strongly favoring the development of the large molecule drug substance CDMO market. As per estimations of the U.S. Centers for Medicare and Medicaid Services (CMS), national health expenditure estimated to be USD 5.6 trillion by the end of 2025 with the contribution of hospitals around USD 1.8 trillion and to further increase to USD 8.6 trillion by 2033. This acceleration in healthcare spending, especially towards biologics-based treatments like monoclonal antibodies, cell and gene therapy, and complex specialty drugs, is fueling the growth of the market.
Growth of Biologics and Monoclonal Antibody Manufacturing: The growing use of biologics therapies and monoclonal antibodies is creating more outsourcing opportunities within the biopharmaceutical sector. There has been collaboration between pharmaceutical/biotechnology firms and CDMOs to enhance development and production capacity, as well as gain biologics expertise. Monoclonal antibodies are commonly employed in the treatment of cancers, autoimmune disorders, and rare diseases, thus enhancing the pipeline of biologics development. CDMOs are investing in bioreactors of large capacities, advanced cell cultures, and flexible GMP facilities to increase production capacity.
Expansion of Cell and Gene Therapy Manufacturing: The increase in the number of cell and gene therapies is prompting CDMOs to build capacity to manufacture such therapies through advanced manufacturing techniques. They are setting up production units that deal with viral vectors, cell processing, clean rooms, and facilities that meet good manufacturing practices (GMP). Increasing demands for personalized medicine and regenerative therapies have also compelled them to work on developing large-scale manufacturing techniques.CDMOs help biotech companies in fulfilling their regulatory responsibilities and also facilitate clinical trials as well as the commercialization of cell and gene therapy products.
Segmental Insights
By Product
By product the market is segmented into biosimilars and biologics. Biologics led the U.S. large molecule drug substance CDMO market with 77.25% share in 2025, driven by the growth in demand for monoclonal antibodies, cell and gene therapies, and cutting-edge biologic therapeutics for oncology and autoimmune diseases.
Biosimilars projected to grow rapidly with 7.5% CAGR, fueled by patent expirations of several blockbuster biologics and growing take-up of cost-saving alternatives across U.S. healthcare systems.
By Service
In terms of service, the market is divided into contract development and contract manufacturing. Contract manufacturing held the highest market share of 67.05% due to increasing dependence by pharmaceutical and biotechnology firms on CDMOs for high-volume GMP-capable production in order to expedite commercial timelines.
Contract development services are anticipated to grow at a fast pace, due to rising outsourcing of process development, scale-up, and analytical services to mitigate early-stage R&D risk and expense.
By Source
Based on source, the market is segmented into mammalian, microbial, and others. Mammalian expression systems dominated the market, due to its rising adoption in production of complex biologics like monoclonal antibodies and recombinant proteins with great precision and safety.
Microbial systems are expected to register robust growth rate of CAGR 8.2% due to their cost-effectiveness and efficiency in the production of enzymes, peptides, and biosimilars on a large scale.
By End-use
By end-use, the industry is categorized into biotech firms, contract research organizations (CROs), and others. Biotech firms represent the highest market share of 54.30% driven by its reliance on CDMOs for process development, commercial manufacturing, and clinical-scale supply in order to steer clear of infrastructure expense.
CRO are expected to expand at a high growth rate over the forecast period, fueled by increasing demand for end-to-end fully integrated development-to-commercialization models.
Key Players & Competitive Analysis
The U.S. large molecule drug substance CDMO market is moderately competitive, with significant investments in biologics process development, adaptable manufacturing capacity, and leading-edge bioprocess technologies to enable monoclonal antibodies, cell & gene therapies, recombinant proteins, and next-generation biologics. Companies are making single-use bioreactor platforms, digital biomanufacturing, AI-enabled process optimization, and accelerated regulatory-compliant scale-up models a priority to support biotech and pharmaceutical innovators with reduced time-to-clinic and time-to-market.
Who are the major players in U.S. large molecule drug substance CDMO market?
Key companies active in the U.S. large molecule drug substance CDMO market include AGC Biologics, Inc., Boehringer Ingelheim International GmbH, Catalent, Inc., Eurofins Scientific SE, FUJIFILM Diosynth Biotechnologies U.S.A., Inc., Lonza Group AG, Patheon Inc. (Thermo Fisher Scientific Inc.), Recipharm AB, Rentschler Biopharma SE, Samsung Biologics Co., Ltd., Sartorius AG, Siegfried Holding AG, Syngene International Limited, Wuxi Biologics (Cayman) Inc., and Zymo Research Corp.
Key Players
- AGC Biologics, Inc.
- Boehringer Ingelheim International GmbH
- Catalent, Inc.
- Eurofins Scientific SE
- FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
- Lonza Group AG
- Patheon Inc. (Thermo Fisher Scientific Inc.)
- Recipharm AB
- Rentschler Biopharma SE
- Samsung Biologics Co., Ltd.
- Sartorius AG
- Siegfried Holding AG
- Syngene International Limited
- Wuxi Biologics (Cayman) Inc.
- Zymo Research Corp.
U.S. Large Molecule Drug Substance CDMO Industry Developments
March 2026: Samsung Biologics announced the completion of the acquisition of a manufacturing facility in Rockville, Maryland, from GSK. According to Samsung Biologics, the acquisition marks its first manufacturing presence in the U.S. (source: samsungbiologics.com)
U.S. Large Molecule Drug Substance CDMO Market Segmentation
By Product Outlook (Revenue, USD Billion, 2021–2034)
- Biologics
- Biosimilar
By Services Outlook (Revenue, USD Billion, 2021–2034)
- Contract Manufacturing
- Clinical
- Commercial
- Contract Development
- Cell Line Development
- Process Development
By Source Outlook (Revenue, USD Billion, 2021–2034)
- Mammalian
- Microbial
- Others
By End-Use Outlook (Revenue, USD Billion, 2021–2034)
- Biotech Companies
- CRO
- Others
U.S. Large Molecule Drug Substance CDMO Market Report Scope
| Report Attributes | Details |
| Market Size in 2025 | USD 13.23 Billion |
| Market Size in 2026 | USD 13.57 Billion |
| Revenue Forecast by 2034 | USD 25.37 Billion |
| CAGR | 7.5% from 2026 to 2034 |
| Base Year | 2025 |
| Historical Data | 2021–2024 |
| Forecast Period | 2026–2034 |
| Quantitative Units | Revenue in USD Billion and CAGR from 2026 to 2034 |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Industry Trends |
| Segments Covered |
|
| Competitive Landscape |
|
| Report Format |
|
| Customization | Report customization as per your requirements with respect to country, and segmentation. |
FAQ's
The market size was valued at USD 13.23 billion in 2025 and is projected to grow to USD 25.37 billion by 2034.
The market is projected to register a CAGR of 7.5% during the forecast period.
A few of the key players in the market are AGC Biologics, Inc., Boehringer Ingelheim International GmbH, Catalent, Inc., Eurofins Scientific SE, FUJIFILM Diosynth Biotechnologies U.S.A., Inc., Lonza Group AG, Patheon Inc. (Thermo Fisher Scientific Inc.), Recipharm AB, Rentschler Biopharma SE, Samsung Biologics Co., Ltd., Sartorius AG, Siegfried Holding AG, Syngene International Limited, Wuxi Biologics (Cayman) Inc., and Zymo Research Corp.
The biologics segment dominated the market with 77.25% revenue share in 2025.
Contract development services are anticipated to grow at a fast pace, due to rising outsourcing of process development
Download Sample Report of U.S. Large Molecule Drug Substance CDMO Market
Please fill out the form to request a customized copy of the research report.
